The charts on this page feature a breakdown of the total annual pay for the top executives at CymaBay Therapeutics, Inc. as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. CymaBay Therapeutics, Inc. income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. CymaBay Therapeutics, Inc. annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Sujal Shah
President and Chief Executive Officer
Total Cash $722,874 Equity $1,211,685 Other $3,458 Total Compensation $1,938,017
Charles A. McWherter Ph.D.
Chief Science Officer
Total Cash $575,694 Equity $1,211,685 Other $4,738 Total Compensation $1,792,117
Daniel Menold
Vice President, Finance
Total Cash $349,914 Equity $504,869 Other $2,479 Total Compensation $857,262
Paul Quinlan
General Counsel
Total Cash $533,725 Equity $2,423,370 Other $4,189 Total Compensation $2,961,284
Pol Boudes M.D.
Chief Medical Officer
Total Cash $575,694 Equity $1,009,738 Other $4,884 Total Compensation $1,590,316
For its 2018 fiscal year, CymaBay Therapeutics, Inc., listed the following board members on its annual proxy statement to the SEC.
Carl Goldfischer, M.D. Total Cash $181,028
Caroline Loewy Total Cash $166,528
Evan A. Stein, M.D., Ph.D. Total Cash $161,528
Kurt von Emster, CFA Total Cash $175,278
Paul F. Truex Total Cash $171,528
Robert F. Booth, Ph.D. Total Cash $163,528
Robert J. Weiland Total Cash $166,528
Robert J. Wills, Ph.D. Total Cash $183,528

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.